[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.204.108.121. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 594
Citations 0
Comment & Response
October 2014

Treating Idiopathic Intracranial Hypertension

Author Affiliations
  • 1Neurotrauma and Neurodegeneration, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, The Medical School, University of Birmingham, Birmingham, England
  • 2Birmingham Neuro-Ophthalmology Unit, Ophthalmology Department, University Hospitals Birmingham NHS Trust, Queen Elizabeth Hospital Birmingham, Birmingham, England
  • 3Neurology Department, University Hospitals Birmingham NHS Trust, Queen Elizabeth Hospital Birmingham, Birmingham, England
JAMA Neurol. 2014;71(10):1326-1327. doi:10.1001/jamaneurol.2014.2360

To the Editor In their article regarding the Idiopathic Intracranial Hypertension (IIH) Treatment Trial (IIHTT), Wall and colleagues stated that “there are no properly designed and executed clinical trials to guide therapy.”1 They quoted Lueck and McIIwaine2 who correctly concluded a dearth of properly designed clinical trials in IIH at the time of their publication. In using this article, Wall et al1 did not consider a number of important published studies in the intervening 5 years since this Cochrane review2 was updated in 2008.

First Page Preview View Large
First page PDF preview
First page PDF preview
×